


# Membranous Nephropathy Market Size is anticipated to Grow by 2032, estimates DelveInsight

## Membranous Nephropathy Market

LAS VEGAS, NEVADA, UNITED STATES, March 27, 2024 /EINPresswire.com/ -- DelveInsight's "Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.



## Key Takeaways from the Membranous Nephropathy Market Research Report

- The Membranous Nephropathy market is expected to grow by factors like an increase in the patient pool, expected entry of emerging therapies.
- According to DelveInsight, IMN affects males and female equally.
- Total Membranous Nephropathy prevalent population in 7MM was estimated to be ~128,000 cases in 2021 and is expected to increase during the study period [2019–2032].
- The leading Membranous Nephropathy Companies working in the market include Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.
- Promising Membranous Nephropathy Pipeline Therapies in the various stages of development

include B007, VB119, MIL62, Cyclosporine, SNP-ACTH (1-39) Gel, Rituximab, MIL62, Zanubrutinib, Tacrolimus, and others.

- March 2024: Mario Negri Institute for Pharmacological Research announced a study of Phase 2 clinical trials for Obinutuzumab. The first-generation chimeric anti-CD20 monoclonal antibody rituximab is effective in inducing MN remission in the majority of patients, but a significant fraction of them can experience disease relapses that require multiple re-treatments over time. Repeated infusions may result in hypersensitivity reactions, which contraindicate further treatment with rituximab. Independent of previous treatment response, Rituximab-Intolerant patients require a safe and effective therapeutic alternative that could reduce the risk of hypersensitivity reactions. On the other end a substantial proportion of patients do not benefit of rituximab therapy and might benefit of other anti CD20 monoclonal antibodies.
- March 2024: Alpine Immune Sciences Inc. announced a study of Phase 1 & 2 povetacicept. The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases.
- March 2024: Argenx announced a study of Phase 2 clinical trials for efgartigimod IV. To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).

Discover which therapies are expected to grab the Membranous Nephropathy market share @ [Membranous Nephropathy Market Outlook](#)

## Membranous Nephropathy Overview

Membranous Nephropathy (MN), also known as membranous glomerulonephritis (MGN) is a rare autoimmune disorder characterized by a pathological change in the glomerular basement membrane (GBM) due to deposition of subepithelial immune complexes.

## Membranous Nephropathy Epidemiology Segmentation in the 7MM

- Membranous Nephropathy Prevalence Cases
- Membranous Nephropathy Type Specific Prevalence Cases
- Membranous Nephropathy Prevalence by Antigens cases

Download the report to understand which factors are driving Car Membranous Nephropathy epidemiology trends @ [Membranous Nephropathy Epidemiological Insights](#)

## Membranous Nephropathy Market Landscape

In a nutshell, it can be summarized that as a result of discovery of new aspects of disease etiology more potential therapeutic targets are being identified leading to surge in potential therapies are being investigated for the management of idiopathic membranous nephropathy, it is safe to predict that the treatment space will experience significant reconstitution during the forecast period of 2023–2032.

## Membranous Nephropathy Market Insights

Membranous Nephropathy is an autoimmune disease caused by antibodies mostly directed to podocyte antigens and characterized by very high levels of protein in urine, edema, hypoalbuminemia, and elevated serum lipids. Membranous Nephropathy is typically divided into primary MN when there is no underlying disease association, and secondary Membranous Nephropathy when there is an underlying disease association such as autoimmune disease (most commonly lupus), malignancy, infection or temporal association with the use of certain drugs.

## Membranous Nephropathy Emerging Drugs Profile

- Calcineurin inhibitors
- Rituximab
- Steroids
- Alkylating agents and others

## Membranous Nephropathy Treatment Landscape

Membranous Nephropathy treatment is initially put on the supportive therapies regardless of their base etiologies. There are therapies that are undergoing investigational analysis for the same. Pharmaceutical giants like Hoffmann-La Roche, Novartis, MorphoSys, and others have their candidates in the pipeline. These candidates are being analyzed for their safety, efficacy, and other parameters under different clinical trials. Recently, MorphoSys presented their interim results for their drug candidate Felzartamab (MOR202) to treat membranous nephropathy. During their M-PLACE study, it was observed that most of the patients have shown positive as per the analysis. The safety profile of the drug was found to be consistent as per the mechanism of the drug. The treatment-emergent adverse events were manageable.

## Membranous Nephropathy Drugs Uptake

Roche's Obinutuzumab is a humanized and glycoengineered type II anti-CD20 monoclonal antibody with superior in vitro B-cell cytotoxicity than rituximab. Obinutuzumab is directed at a different epitope on CD20 than that recognized by rituximab and can evoke a greater B-cell apoptotic response. Modification of the glycan tree structure at the Fc fragment of obinutuzumab leads to an increased affinity to FcγRIII and thereby potentiates antibody-

dependent cellular cytotoxicity via natural killer cells as well as antibody-dependent cellular phagocytosis via macrophages. These B-cell depletion mechanisms contrast to the primarily complement-dependent cytotoxicity for rituximab. Currently, the drug is in Phase III developmental stage.

Iptacopan (LNP023), by Novartis, is a first-in-class, orally-administered, potent, and highly selective factor B inhibitor of the alternative complement pathway. Iptacopan binds to FB to suppress the activity of C3 convertase and thus signaling from the alternative complement pathway (AP) and activation of the amplification loop. This prevents downstream generation of the C5 convertase complex, opsonization, and formation of C3a and C5a anaphylatoxins and membrane attack complex (MAC). Direct classical and lectin pathway signaling remains intact, resulting in a potentially lower meningococcal infection risk in vaccinated patients compared to terminal complement pathway inhibitors.

Felzartamab (MOR202) is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HIBio) obtained exclusive rights to develop and commercialize felzartamab across all indications worldwide, with the exception of Greater China. On behalf of HIBio, MorphoSys is evaluating felzartamab for patients with two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial).

VB119 is an IgG1 mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) and potent binding to CD19, a B-cell surface receptor found on autoantibody-secreting cells (ASCs). ASCs are closely linked to several autoimmune diseases, including membranous nephropathy (MN). Pathogenic ASCs often lack expression of CD20 and are not targeted by anti-CD20 antibodies such as rituximab.

## Scope of the Membranous Nephropathy Market Report

- Coverage- 7MM
- Study Period- 2019-2032
- Membranous Nephropathy Companies- Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.
- Membranous Nephropathy Pipeline Therapies- B007, VB119, MIL62, Cyclosporine, SNP-ACTH (1-39) Gel, Rituximab, MIL62, Zanubrutinib, Tacrolimus, and others.
- Membranous Nephropathy Market Dynamics: Membranous Nephropathy Market Drivers and Barriers

Discover more about Membranous Nephropathy Drugs in development @ [Membranous Nephropathy Ongoing Clinical Trials Analysis](#)

## Table of Content

1. Key Insights
2. Membranous Nephropathy Executive Summary
3. Competitive Intelligence Analysis for Membranous Nephropathy
4. Membranous Nephropathy: Market Overview at a Glance
5. Membranous Nephropathy: Disease Background and Overview
6. Patient Journey
7. Membranous Nephropathy Epidemiology and Patient Population
8. Membranous Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Membranous Nephropathy Unmet Needs
10. Key Endpoints of Membranous Nephropathy Treatment
11. Membranous Nephropathy Marketed Products
12. Membranous Nephropathy Emerging Therapies
13. Membranous Nephropathy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Membranous Nephropathy Market Outlook
16. Membranous Nephropathy Market Access and Reimbursement Overview
17. Membranous Nephropathy KOL Views
18. Membranous Nephropathy Market Drivers
19. Membranous Nephropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

## About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj  
DelveInsight  
+91 9650213330  
ybhardwaj@delveinsight.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/699131236>  
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.